# Severity of Prior COVID-19 Infection is Associated with Postoperative **Outcomes Following Major Inpatient Surgery**

Nathaniel B. Verhagen<sup>1</sup>, Gopika SenthilKumar<sup>1,2</sup>, Taylor Jaraczewski<sup>1</sup>, Nicolas K. 3 Koerber<sup>1</sup>, Jennifer R. Merrill<sup>1</sup>, Madelyn A. Flitcroft<sup>1</sup>, Aniko Szabo<sup>3</sup>, Anjishnu Banerjee<sup>3</sup>, 4 Xin Yang<sup>4</sup>, Bradley W. Taylor<sup>4</sup>, Carlos E. Figueroa Castro<sup>5</sup>, Tina W.F. Yen<sup>1</sup>, Callisia N. 5 Clarke<sup>1</sup>, Kathryn Lauer<sup>6</sup>, Kurt J. Pfeifer<sup>7</sup>, Jon C. Gould<sup>8</sup>, Anai N. Kothari<sup>1,4</sup>; on behalf of 6 7 the N3C Consortium 8 <sup>1</sup>Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, 9 Milwaukee, WI 10 <sup>2</sup>Department of Physiology and Anesthesiology, Medical College of Wisconsin, 11 Milwaukee, WI 12 <sup>3</sup>Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI <sup>4</sup>Clinical and Translational Science Institute of Southeastern Wisconsin, Medical College 13 14 of Wisconsin, Milwaukee, WI

- <sup>5</sup>Department of Medicine, Division of Infectious Diseases, Medical College of Wisconsin, 15 16 Milwaukee, WI
- 17 <sup>6</sup>Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI
- 18 <sup>7</sup>Department of Medicine, Section of Perioperative & Consultative Medicine, Medical

19 College of Wisconsin, Milwaukee, WI

20 <sup>8</sup>Department of Surgery, Division of Minimally Invasive and GI Surgery, Medical College 21 of Wisconsin, Milwaukee, WI

#### 24 **Corresponding Author:**

- 25 Anai N. Kothari, MD MS FSSO
- Medical College of Wisconsin 26
- 27 Division of Surgical Oncology
- 28 8701 W Watertown Plank Road
- 29 Milwaukee, Wisconsin 53226, USA
- 30 (414)955-1443

1

2

22

23

31 akothari@mcw.edu

### **ABSTRACT**

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

**Objective:** To determine the association between severity of prior history of SARS-CoV-2 infection and postoperative outcomes following major elective inpatient surgery. **Summary Background Data:** Surgical guidelines instituted early in the COVID-19 pandemic recommended delay in surgery up to 8 weeks following an acute SARS-CoV-2 infection. Given that surgical delay can lead to worse medical outcomes, it is unclear if continuation of such stringent policies is necessary and beneficial for all patients. especially those recovering from asymptomatic or mildly symptomatic COVID-19. Methods: Utilizing the National Covid Cohort Collaborative (N3C), we assessed postoperative outcomes for adults with and without a history of COVID-19 who underwent major elective inpatient surgery between January 2020 and February 2023. COVID-19 severity and time from SARS-CoV-2 infection to surgery were each used as independent variables in multivariable logistic regression models. **Results:** This study included 387,030 patients, of which 37,354 (9.7%) had a diagnosis of preoperative COVID-19. History of COVID-19 was found to be an independent risk factor for adverse postoperative outcomes even after a 12-week delay for patients with moderate and severe SARS-CoV-2 infection. Patients with mild COVID-19 did not have an increased risk of adverse postoperative outcomes at any time point. Vaccination decreased the odds of mortality and other complications. **Conclusions:** Impact of COVID-19 on postoperative outcomes is dependent on severity of illness, with only moderate and severe disease leading to higher risk of adverse outcomes. Existing wait time policies should be updated to include consideration of COVID-19 disease severity and vaccination status.

### INTRODUCTION

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

As of February 2023, over 100 million cases of SARS-CoV-2 infections have been reported in the US<sup>1</sup>. Among those with prior infection, 15–20% will require elective surgery<sup>2</sup>. Prior history of COVID-19 infection is associated with adverse postoperative outcomes and complications<sup>3-6</sup>, and this risk can persist up to eight weeks after infection<sup>5</sup>. Accordingly, early in the pandemic, several groups recommended a delay in surgery for 7–8 weeks following a COVID-19 infection<sup>5,7</sup>. While these guidelines attempted to mitigate the risk of COVID-19 by delaying surgery, as the pandemic transitions to an endemic phase, there is a paucity of data to guide the de-implementation of these policies. This is especially important when also considering that delaying care can worsen both short- and long-term health outcomes<sup>8</sup>. In addition, delayed surgical care can lead to prolonged poor quality of life including chronic pain, impaired mobility, and inability to work. The severity of a SARS-CoV-2 infection can vary widely from mild flu-like symptoms or no symptoms to systemic disease requiring hospitalization and even critical care. Most current guidelines for managing COVID-19 in the perioperative setting are not stratified by disease severity; however, there appears to be a relationship between severity of infection and postoperative outcomes<sup>8</sup>. Prior studies also show that compared to those with asymptomatic or mild disease, postoperative intensive care unit stay is higher among those with severe COVID-19 who require hospitalization9. This suggests that including severity of SARS-CoV-2 infection in surgical wait time guidelines may facilitate more personalized patient recommendations and prevent unnecessary delays to

surgery for those with less severe infections. In addition, since disease severity can be lowered through vaccination<sup>2</sup>, and as of February 2023, over 269 million people in the US received at least 1 dose of COVID-19 vaccine<sup>1</sup>, the impact of preoperative vaccination among patients who present with COVID-19 prior to requiring surgery must be taken into consideration. The primary objective of this study was to measure the association between the severity of SARS-CoV-2 infection prior to major elective surgery and postoperative adverse outcomes. Secondary objectives included investigating how severity should be considered in surgical wait time guidelines and the influence of vaccination on postoperative outcomes. **METHODS** 

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Electronic health record data from the National COVID Cohort Collaborative (N3C), the largest multi-site centralized data source of COVID-19 patients in the United States, was retrospectively analyzed using the N3C Data Enclave. PCORnet, TriNetX, OMOP, and ACT are the primary data sources that contribute to N3C. A detailed description of the N3C's rationale, design, infrastructure, and deployment has been previously reported. Patients 18 years and older who underwent major inpatient surgery between January 2020 and February 2023 were included, and the surgical procedures were selected based on prior literature assessing the role of COVID-19 on surgical outcomes<sup>5</sup>. The following were included: hip arthroplasty, knee arthroplasty, laminectomy, spinal arthrodesis, craniectomy, aortic aneurysm repair, lung excision,

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

coronary artery bypass graft, esophagectomy, mastectomy, prostatectomy, colectomy, gastrectomy, hepatectomy, and pancreatectomy (Supplemental Table 1). Patient characteristics (sex, age, race and ethnicity, Charlson Comorbidity Index)<sup>11</sup>, were identified using the N3C's Shared Knowledge Store patient fact table. Standard SNOMED codes from the Observational Health Data Science and Informatics' (OHDSI) ATLAS tool were used to identify elective inpatient procedures and patients' comorbidities (Supplemental Table 1,2). Exclusion criteria included undergoing natural orifice, percutaneous, endoscopic, diagnostic (unless open surgery), or transplant procedures. For patients with multiple surgeries, the first surgery after SARS-CoV-2 infection was used. COVID-19 positivity was defined as having a positive lab measurement (PCR or antigen) or a positive COVID-19 diagnosis (ICD10-CM code U07.1) any time before surgery. Patients with COVID-19 within 24 hours of surgery were excluded. The severity of a patient's COVID-19 was determined using the World Health Organization's (WHO) Clinical Progression Scale (CPS)<sup>11</sup>. Patient-specific severity was obtained from the N3C Knowledge Store and derived from critical visits associated with COVID positivity. Mild severity was defined as having outpatient visit only (WHO Severity 1–3). Moderate severity was defined as requiring hospitalization without pulmonary support (WHO Severity 4–6). Severe disease was defined as needing hospitalization with extracorporeal membrane oxygenation (ECMO or invasive ventilation, WHO Severity 7-9)<sup>12</sup>. The N3C Knowledge Store was used to determine the vaccination status of patients. Fully vaccinated patients were defined as having either received a single dose of the viral vector vaccine or two doses of mRNA vaccine at least 14 days before their

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

first SARS-CoV-2 infection. Patients who received only one dose of the mRNA vaccine or were vaccinated after a COVID-19 diagnosis were not considered fully vaccinated. The primary outcome of the study was a 30-day composite adverse postoperative event and included the following: mortality, unplanned readmission, acute myocardial infarction, cardiac arrhythmia, deep vein thrombosis, pneumonia, pulmonary embolism, renal failure, respiratory failure, sepsis, and urinary tract infection. Each individual 30day complication included in the composite outcome was also separately evaluated. Outcomes were constructed using SNOMED codes and concepts associated with chronic conditions or directly caused by COVID-19 were excluded (Supplemental Table 3). Unadjusted baseline characteristics and comparisons between patients with and without prior COVID-19 were analyzed using standard descriptive statistics. Adjusted analyses were performed using multivariable logistic regression models. Separate models were fit for each outcome with covariates that included age, sex, race and ethnicity, Charlson Comorbidity Index (CCI), and relative surgical risk. Relative surgical risk is a computed feature based on the expected median length of stay for a given procedure. Additional logistic regression models were fit to measure the association between 30-day postoperative adverse outcomes and (1) time between SARS-CoV-2 infection and surgery, (2) disease severity, and (3) vaccination status. Within each disease severity group, the risk of 30-day postoperative adverse outcomes as a factor of time between infection and surgery was analyzed. All analysis were conducted using the N3C Data Enclave using the tidyverse, ggplot2, gtsummary, splines, and broom R packages.

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

**RESULTS** 387,030 patients were included in the study and 37,354 (9.7%) had a preoperative diagnosis of COVID-19. Table 1 details baseline patient demographics and characteristics in those with and without a history of COVID-19. History of COVID-19 and 30-day postoperative adverse outcomes On unadjusted analysis, rate of 30-day postoperative adverse events was greater in patients with a history of COVID-19 than those without (22.7% vs. 21.5%, P<0.001, Table 1). Additionally, the rates of 30-day mortality (1.8% vs. 1.4%), postoperative pulmonary embolism (1.4% vs. 1.2%; P=0.008), renal failure (6.9% vs. 6.4%; P<0.001), sepsis (3.2% vs. 2.9%; P=0.007), and composite non-fatal event (22% vs. 21%; P<0.001) were all significantly greater in patients with a history of COVID-19 (Table 1). Following adjustment for age, sex, race, ethnicity, smoking status, comorbid disease, and relative risk of surgery, patients with a history of COVID-19 had greater odds of 30day composite adverse postoperative events (aOR 1.09 [1.06–1.12]; Figure 1). Association of time between SARS-CoV-2 infection and surgery and 30-day postoperative adverse outcomes Patients were stratified based on timing of surgery relative to SARS-CoV-2 infection. Groups included 0-4 weeks (N=7,425, 19.9%), 4-8 weeks (N=3,936, 10.5%), 8-12 weeks (N=2,604, 7.0%) and 12+ weeks (N=23,389, 62.6%). Patients who underwent surgery 0–4 weeks after COVID-19 had overall higher rates of postoperative adverse events, including mortality (3.3% vs. 1.4%; P<0.001) and any non-fatal complications

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

(26% vs. 21%, P<0.001), when compared to patients without COVID-19 (Supplemental Table 4). On adjusted analysis (Figure 2, Supplemental Table 5), patients who underwent surgery within 4 weeks of SARS-CoV-2 infection had increased odds of 30day postoperative composite adverse event (aOR 1.27 [1.20–1.35]), mortality (aOR 2.34 [2.05–2.67]), deep vein thrombosis (aOR 1.33 [1.12–1.57]), pneumonia (aOR 1.60 [1.43–1.79]), pulmonary embolism (aOR 1.44 [1.20–1.70]), renal failure (aOR 1.28 [1.17–1.39]), respiratory failure (aOR 1.53 [1.40–1.66]), and sepsis (aOR 1.52 [1.36– 1.69]). The odds of composite adverse postoperative outcome returned to baseline at 12 weeks following infection (aOR 1.01 [0.98–1.05] at 12+ weeks). Association of severity of SARS-CoV-2 infection and 30-day postoperative adverse outcomes Patients were next stratified based on the severity of their SARS-CoV-2 infection prior to surgery, and 31,677 (84.8%), 5,009 (13.4%), and 655 (1.8%) patients had mild, moderate, and severe disease, respectively. Incidence of adverse 30-day postoperative outcomes increased with severity across all measured outcomes (Supplemental Table 6), and patients with severe disease had the highest rate of mortality (14% vs. 1.4%), any non-fatal complication (60% vs. 21%), and hospital readmission (18% vs. 11%) when compared to patients without COVID-19 history (P<0.001 all). After adjusting for patient demographics, risk of surgery, and comorbidities, patients with moderate and severe disease had higher odds for all assessed adverse events except for pulmonary embolism for moderate COVID-19 (aOR 1.19 [0.96–1.45]) and hospital readmission for severe COVID-19 (aOR 1.20 [0.98–1.46]) (Figure 3, Supplemental Table 7).

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

The interplay between timing of surgery and COVID-19 disease severity in influencing risk for 30-day composite postoperative complications For each COVID-19 severity group (mild, moderate, severe), the adjusted odds of having a composite adverse postoperative event were measured (Figure 4). Patients with mild COVID-19 infections did not demonstrate an increased risk, regardless of the time between infection and surgery. Patients with moderate disease were observed to have increased risk for composite adverse events at 0–4 weeks (aOR 1.84 [1.61–2.10]) that persisted beyond 12 weeks between COVID-19 and surgery (aOR 1.36 [1.25– 1.48) when compared to patients without prior history of COVID-19. The magnitude of risk was greater for patients with severe disease, with highest odds for an adverse event occurring if surgery was performed within 4 weeks of SARS-CoV-2 infection (aOR 8.41 [6.42–11.1]). This risk did decrease with time, though it remained elevated when compared to patients who did not have prior COVID-19 (aOR 2.22 [1.66–2.95] at 12+ weeks). Preoperative vaccination and 30-day postoperative adverse outcomes In patients with COVID-19 prior to surgery, vaccination significantly decreased rates of pneumonia (2.3% vs. 3.0%; P=0.003), respiratory failure (4.2% vs. 5.6%; P<0.001), and sepsis (2.7% vs. 3.3%; P<0.05) (Supplemental Table 8). After adjustment for patient demographics, comorbidities, and relative risk of surgery, vaccination was associated with decreased odds of mortality (aOR 0.76 [0.59–0.95]), pneumonia (aOR 0.73 [0.60– 0.88]), respiratory failure (aOR 0.72 [0.62–0.83]), and sepsis (aOR 0.79 [0.66–0.94]) (Figure 5).

### **DISCUSSION**

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

In this study, we aimed to understand how the severity of a SARS-CoV-2 infection prior to major elective inpatient surgery influences postoperative outcomes using the N3C Data Enclave—a harmonized electronic health data platform comprising over 70 institutions and more than 18,000,000 patients<sup>10</sup>. Our findings demonstrate that a prior history of COVID-19 is an independent risk factor for adverse surgical outcomes, and the risk remains elevated for 12 weeks after a SARS-CoV-2 infection; however, this is dependent on the severity of COVID-19. Patients with mild disease (not requiring hospitalization) did not have an elevated risk of adverse outcomes regardless of the timing of surgery. Those with moderate and severe disease had persistently elevated surgical risk that lasted 12+ weeks after an acute infection. The results of this study are consistent with prior work examining surgical outcomes in patients with a history of SARS-CoV-2 infection conducted early in the pandemic. The COVIDSurg Collaborative, a multinational collaborative that aimed to explore the impact of COVID-19 in surgical patients and services, published the first population-level study assessing surgical outcomes following a SARS-CoV-2 infection. They found an increased risk of surgical mortality that lasted for 7 weeks following an acute infection. Another large-scale study by Deng and colleagues confirmed these findings in a United States population and advocated for a wait time of 8 weeks from the time of a SARS-CoV-2 infection before proceeding with elective surgery<sup>5</sup>. In response to these data (and other similar findings from single institution series), expert guidelines suggested delaying elective surgery 7 weeks while weighing the time-sensitivity of the intervention<sup>13</sup>. These studies and guidelines were crucial given the novel situation

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

perioperative providers were faced with early in the COVID-19 pandemic as an increasing number of patients with prior SARS-CoV-2 infection required elective surgery. Still, several gaps remain in the evidence base for guiding the management of this patient population which are now addressed by this study. We re-demonstrate the risk for adverse 30-day composite postoperative outcomes remains elevated for 8 weeks after a SARS-CoV-2 infection; however, when stratified by severity, this risk only is present in those recovered from moderate and severe infections (anyone who required hospitalization). Those with mild disease were not at increased risk of composite adverse outcomes even when undergoing surgery within 4 weeks of an acute infection which is consistent with prior work<sup>8</sup>. We also provide a more detailed measurement of the association across a spectrum of specific postoperative complications. For example, patients with mild disease had no increased odds for all assessed adverse events, moderate disease showed elevated risk for all assessed complications, while those with severe disease had increased odds of all assessed complications with a magnitude of effect multiple-fold greater. This study also provides evidence that vaccination can reduce the risk of adverse postoperative events in patients with a prior history of COVID-19. The data presented in this study include patients who underwent surgery prior to March 2023 and thus reflects the current environment as the pandemic shifts to an endemic phase. As a comparison, data collected for the COVIDSurg study was in October of 2020, and the Deng et al. study of patients in the United States included surgeries performed until June of 2021. Equipped with the updated data presented in this study,

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

we propose the following guidance for managing patients prior to inpatient elective surgery. First, all patients who are planned to undergo surgery should be assessed for their history of COVID-19, including detailed information regarding the severity of their infection. Those with a prior history should be classified as having either asymptomatic/mild disease or moderate/severe disease. After this determination is made, patients with asymptomatic/mild disease should have their surgery delayed at least 5 days from the time of positive test to ensure they do not develop progressive symptoms that increase the severity of illness. If they remain asymptomatic/mild after this wait time, our data supports the safety of proceeding with elective surgery. However, if the patient has moderate/severe disease or develops moderate/severe disease, then consideration should be made for delaying surgery while also considering the risk/benefit ratio of potential harms related to a prolonged delay in circumstances of time-sensitive surgical indications. Since we do not observe a return to baseline risk even beyond 12 weeks in patients with moderate/severe disease, no standard time for delay can be recommended. Instead, we advocate for early engagement with perioperative medicine teams and/or dedicated long COVID clinics to identify strategies for optimal risk reduction and provide objective assessment of physiologic recovery prior to proceeding with surgery. At our institution, all patients with a history of moderate/severe disease are recommended to be referred to preoperative clinic for assessment prior to procedure to assess for recovery and help collaboratively determine the optimal timing for surgery. Developing and applying machine learning/artificial intelligence tools using the N3C Data Enclave are active areas of work

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

in our group to help provide more specific guidance for patients with a history of moderate or severe SARS-CoV-2 infection. There are several limitations to our study that must be carefully considered when interpreting the results. The use of electronic health record data within N3C Data Enclave may introduce biases that are well-described in prior studies<sup>14</sup>. Methods specific to N3C can help manage several of these through rigorous data standardization, a highly engaged user community, and a centralized platform for handling all data-related tasks including extraction, processing, and analyses. Another source of bias is the selection of patients to undergo surgery after recovering from a prior COVID-19 infection. Detailed information on preoperative evaluation, indications, and rationale for proceeding with surgery prior to 7 weeks in patients with prior COVID-19 is not available. Additionally, we were unable to directly measure the association between SARS-CoV-2 variants and outcomes—though, this likely is indirectly accounted for in analyses that include severity. Despite these potential shortcomings, leveraging the largest COVID-19-specific national data provides a unique opportunity to help guide the management of patients with previous SARS-CoV-2 infections undergoing elective surgery. In conclusion, prior COVID-19 infection is a risk factor for adverse postoperative outcomes following major inpatient elective surgery. The magnitude and duration of this risk is dependent on the severity of COVID-19 infection and is reduced in vaccinated patients. As the pandemic transitions to an endemic phase, the results of this study emphasize a one-sized-fits-all approach to risk stratification in this patient population

can lead to unnecessary surgical delays, and consensus guidelines should be updated to include consideration of COVID-19 disease severity and vaccination status.

#### **REFERENCES**

- Johns Hopkins Coronavirus Resource Center. <a href="https://coronavirus.jhu.edu/us-map">https://coronavirus.jhu.edu/us-map</a>. Accessed.
- 2. El-Boghdadly K, Cook TM, Goodacre T, et al. SARS-CoV-2 infection, COVID-19 and timing of elective surgery: A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, the Centre for Peri-operative Care, the Federation of Surgical Specialty Associations, the Royal College of Anaesthetists and the Royal College of Surgeons of England. *Anaesthesia*. 2021;76(7):940-946.
- 3. Collaborative CO. Outcomes and Their State-level Variation in Patients
  320 Undergoing Surgery With Perioperative SARS-CoV-2 Infection in the USA: A
  321 Prospective Multicenter Study. *Ann Surg.* 2022;275(2):247-251.
- 322 4. Collaborative CO. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *Lancet.* 2020;396(10243):27-38.
- Deng JZ, Chan JS, Potter AL, et al. The Risk of Postoperative Complications
   After Major Elective Surgery in Active or Resolved COVID-19 in the United
   States. Ann Surg. 2022;275(2):242-246.
- Verhagen NB, Koerber NK, Szabo A, et al. Vaccination Against SARS-CoV-2
   Decreases Risk of Adverse Events in Patients who Develop COVID-19 Following
   Cancer Surgery. *Ann Surg Oncol.* 2022:1-4.
- 7. Collaborative CO, GlobalSurg C. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. *Anaesthesia.* 2021;76(6):748-758.
- SenthilKumar G, Verhagen NB, Sheriff SA, et al. Preoperative SARS-CoV-2
   Infection Increases Risk of Early Postoperative Cardiovascular Complications
   Following Non-Cardiac Surgery. *American Journal of Physiology Heart and Circulatory Physiology*. 2023;Accepted. In Press.
- 338 9. Al Ani A, Tahtamoni R, Mohammad Y, Al-Ayoubi F, Haider N, Al-Mashhadi A.
  339 Impacts of severity of Covid-19 infection on the morbidity and mortality of surgical
  340 patients. *Ann Med Surg (Lond)*. 2022;79:103910.
- Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort
   Collaborative (N3C): Rationale, design, infrastructure, and deployment. *J Am Med Inform Assoc.* 2021;28(3):427-443.
- 11. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis.* 2020;20(8):e192e197.
- 347 12. Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical Characterization and 348 Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using 349 Data From the US National COVID Cohort Collaborative. *JAMA Netw Open.* 350 2021;4(7):e2116901.
- ASA and APSF Joint Statement on Elective Surgery/Procedures and Anesthesia for Patients after COVID-19 Infection. 2022. <a href="https://www.asahq.org/about-asa/newsroom/news-releases/2022/02/asa-and-apsf-joint-statement-on-elective-surgery-procedures-and-anesthesia-for-patients-after-covid-19-infection.">https://www.asahq.org/about-asa/newsroom/news-releases/2022/02/asa-and-apsf-joint-statement-on-elective-surgery-procedures-and-anesthesia-for-patients-after-covid-19-infection.</a>

14. Verheij RA, Curcin V, Delaney BC, McGilchrist MM. Possible Sources of Bias in Primary Care Electronic Health Record Data Use and Reuse. *J Med Internet Res.* 2018;20(5):e185.

355

356

### **TABLES AND FIGURES**

359

360

361362


# Table 1. Patient characteristics and 30-day postoperative adverse outcomes in patients with and without preoperative COVID-19

Characteristics	No Hx of COVID-19 (N = 349,676), No. (%)	Hx of COVID-19 (N = 37,354), No. (%)	P value				
Patient Characteristics							
Age, years							
Median, (Q1-Q3)	63 (52, 72)	61 (49, 70)	< 0.001				
18-29	15166 (4.3%)	1625 (4.4%)	< 0.001				
30-49	60828 (17%)	7734 (21%)					
50-64	111160 (32%)	12838 (34%)					
65+	162522 (46%)	15157 (41%)					
Sex			<0.001				
Female	190052 (54%)	‡20952 (≈56%)					
Male	159505 (46%)	‡16399 (≈44%)					
Missing or Unknown	119 (<0.1%)	20 or fewer					
Race and Ethnicity			<0.001				
Non-Hispanic White	257334 (74%)	25833 (69%)					
Non-Hispanic Black	42740 (12%)	4867 (13%)					
Non-Hispanic Asian	8395 (2.4%)	810 (2.2%)					
Hispanic	21325 (6.1%)	3625 (9.1%)					
Other or Unknown	19930 (5.7%)	2403 (6.4%)					
Smoking Status			< 0.001				
Nonsmoker	304141 (86%)	33151 (89%)					
Current or Former	,						
Smoker	47716 (14%)	4203 (11%)					
Charlson Comorbidity Index (CCI)			<0.001				
0	72432 (21%)	6772 (18%)					
1	42341 (12%)	4412 (12%)					
2	63704 (18%)	6343 (17%)					
3	38900 (11%)	4275 (11%)					
4+	132299 (38%)	15552 (42%)					
Comorbidities	,						
CKD	22374 (6.4%)	3862 (10%)	<0.001				
CHF	20816 (6.0%)	3454 (9.2%)	<0.001				
COPD	21089 (6.0%)	3134 (8.4%)	<0.001				
Coronary Artery Disease	39221 (11%)	5852 (16%)	<0.001				
Depression	35956 (10%)	5875 (16%)	<0.001				
Diabetes	41584 (12%)	7144 (19%)	<0.001				
GERD	58830 (17%)	9432 (25%)	<0.001				


Hypertension	100981 (29%)	14669 (39%)	<0.001
Liver Disease	5730 (1.6%)	977 (2.6%)	<0.001
Obesity	51446 (15%)	8920 (24%)	<0.001
Relative Risk of Surgery			0.058
Low Risk	,	14364 (38%)	
Medium Risk	166702 (48%)	17642 (47%)	
High Risk	48589 (14%)	5348 (14%)	
Vaccine Status			<0.001
Fully Vaccinated	48441 (14%)	5381 (14%)	
Non-Fully Vaccinated	301235 (86%)	31973 (86%)	
Ţ.	postoperative adverse		
Composite Adverse Event		8493 (22.7%)	<0.001
Mortality	, ,	666 (1.8%)	<0.001
Hospital Readmission	38175 (11%)	4248 (11%)	0.008
Any Non-Fatal			
Complication	73555 (21%)	8257 (22%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	1020 (2.7%)	0.13
Cardiac Arrhythmia	34326 (9.8%)	3752 (10%)	0.16
Deep Vein Thrombosis	4648 (1.3%)	532 (1.4%)	0.13
Pneumonia	9623 (2.8%)	1093 (2.9%)	0.053
Pulmonary Embolism	4296 (1.2%)	519 (1.4%)	0.008
Renal Failure	22488 (6.4%)	2592 (6.9%)	<0.001
Respiratory Failure	18862 (5.4%)	2017 (5.4%)	0.97
Sepsis	10244 (2.9%)	1188 (3.2%)	0.007
Urinary Tract Infection	9662 (2.8%)	1045 (2.8%)	0.71

<sup>‡</sup> To comply with N3C policy, counts below 20 are displayed as <20 and additional values were skewed by up to 5 in order to render it impossible to back-calculate precise counts in the 'Missing or Unknown' category. Hx: history; CKD: chronic kidney disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; GERD: gastroesophageal reflux disease.


**Figure 1.** Multivariable regression assessing the association between prior history of COVID-19 and composite 30-day postoperative adverse event. Hx: history; CCI: Charlson Comorbidity Index; aOR: adjusted odds ratio (with 95% confidence interval).




**Figure 2.** Multivariable regression assessing the association between timing of infection relative to surgery and 30-day postoperative adverse events. All models adjusted for age, sex, race and ethnicity, smoking status, comorbid disease, and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence interval).




**Figure 3.** Multivariable regression assessing the association between COVID-19 disease severity and 30-day postoperative adverse outcomes. All models adjusted for age, sex, race and ethnicity, smoking status, comorbid disease, and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence interval).



**Figure 4.** The interplay between timing of surgery and COVID-19 disease severity in influencing odds of composite 30-day postoperative adverse events. All models adjusted for age, sex, race and ethnicity, smoking status, Charlson Comorbidity Index, and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence interval).



**Figure 5.** Multivariable regression assessing the association between full vaccination in patients with a history of COVID-19 and 30-day postoperative adverse events. All models adjusted for age, sex, race and ethnicity, smoking status, Charlson Comorbidity Index, and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence interval).



## **SUPPLEMENTARY DATA**

# **Supplemental Table 1: Surgical Procedures and associated risk**

Procedure Name	Surgery N=387,030 (%)	SNOMED Code
Low Risk		
Hip Arthroplasty	5480 (1.4%)	52734007
Knee Arthroplasty	6034 (1.6%)	609588000
Laminectomy	44462 (11%)	387731002
Mastectomy	75714 (20%)	69031006
Prostatectomy	17059 (4.4%)	90470006
Medium Risk		
Aortic Aneurysm Repair	4881 (1.3%)	233370007
Colectomy	46059 (12%)	23968004
Craniectomy	29201 (7.5%)	36910002
Gastrectomy	7903 (2.0%)	53442002
Lung Excision	17353 (4.5%)	119746007
Spinal Arthrodesis	78947 (20%)	55705006
High Risk		
Coronary Artery Bypass	37492 (9.7%)	232717009
Graft		
Esophagectomy	1538 (0.4%)	45900003
Hepatectomy	8495 (2.2%)	107963000
Pancreatectomy	6412 (1.7%)	33149006

# **Supplemental Table 2: Patient comorbidities**

Preoperative Comorbidities	SNOMED Codes
Chronic Kidney Disease	709044004
Chronic Obstructive Pulmonary Disease	13645005
Coronary Artery Disease	53741008
Depression	370143000
Diabetes	73211009
Gastroesophageal Reflux Disease	235595009
Heart Failure	84114007
Hypertension	59621000
Liver Disease	328383001
Obesity	414916001

# **Supplemental Table 3:** Postoperative Complications

Postoperative Complications	SNOMED Codes
Acute Myocardial Infarction	57054005
Cardiac Arrhythmia	698247007
Deep Vein Thrombosis	128053003
Pneumonia	233604007
Pulmonary Embolism	59282003
Renal Failure	42399005
Respiratory Failure	409622000
Sepsis	91302008
Urinary Tract Infection	68566005

# Supplemental Table 4. Comparison of 30-day postoperative adverse events based on surgical timing relative to COVID-19

Outcomes	No History of COVID-19 (N = 352,947)	0-4 Weeks Post- COVID-19 (N = 7,425)	4-8 Weeks Post- COVID-19 (N = 3,936)	8-12 Weeks Post COVID-19 (N = 2,604)	12+ Weeks Post COVID-19 (N = 23,389)	P value
Mortality	4791 (1.4%)	246 (3.3%)	83 (2.1%)	47 (1.8%)	290 (1.2%)	<0.001
LOS	2 (0, 6)	4 (1, 8)	2 (0, 6)	3 (0, 6)	2 (0, 5)	<0.001
Hospital						
Readmission	38175 (11%)	848 (11%)	458 (12%)	318 (12%)	2622 (11%)	0.057
Any Non-Fatal		1914				
Complication	73555 (21%)	(26%)	890 (23%)	625 (24%)	4828 (21%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	271 (3.6%)	100 (2.5%)	57 (2.2%)	592 (2.5%)	<0.001
Cardiac	34326	211 (0.070)	100 (2.070)	01 (2.270)	002 (2.070)	<b>\0.001</b>
Arrhythmia	(9.8%)	803 (11%)	409 (10%)	286 (11%)	2254 (9.6%)	0.006
Deep Vein	(0.070)	(1170)	,			
Thrombosis	4648 (1.3%)	142 (1.9%)	57 (1.4%)	46 (1.8%)	287 (1.2%)	<0.001
Pneumonia	9623 (2.8%)	348 (4.7%)	131 (3.3%)	95 (3.6%)	519 (2.2%)	<0.001
Pulmonary		,			,	
Embolism	4296 (1.2%)	137 (1.8%)	58 (1.5%)	35 (1.3%)	289 (1.2%)	<0.001
Renal Failure	22488					
	(6.4%)	654 (8.8%)	288 (7.3%)	204 (7.8%)	1446 (6.2%)	<0.001
Respiratory	18862					
Failure	(5.4%)	655 (8.8%)	197 (5.0%)	164 (6.3%)	1001 (4.3%)	<0.001
Sepsis	10244					
	(2.9%)	346 (4.7%)	134 (3.4%)	95 (3.6%)	613 (2.6%)	<0.001
Urinary Tract Infection	9662 (2.8%)	208 (2.8%)	110 (2.8%)	88 (3.4%)	639 (2.7%)	0.43

**Supplemental Table 5.** Multivariable regression assessing the impact of timing of infection relative to surgery on risk on composite and specific 30-day postoperative adverse outcomes. All models adjusted for age, sex, race and ethnicity, smoking status, and relative risk of surgery.

	0–4 weeks (N = 7,425)		4–8 weeks (N = 3,936)		8-12 weeks (N = 2,604)		12+ Weeks (N = 23,389)	
Composite 30-day postoperative outcome	1.27	[1.20-1.35]	1.14	[1.05-1.24]	1.16	[1.05-1.28]	1.01	[0.98-1.05]
Mortality	2.34	[2.05-2.67]	1.57	[1.25-1.95]	1.22	[0.90-1.62]	0.92	[0.81-1.03]
Composite Non- fatal Complications	1.22	[1.15-1.29]	1.10	[1.01-1.20]	1.14	[1.03-1.26]	1.01	[0.98-1.05]
Hospital Readmission	0.99	[0.92-1.07]	1.02	[0.92-1.13]	1.06	[0.94-1.19]	1.01	[0.97-1.05]
Myocardial Infarction	1.13	[0.99-1.29]	0.93	[0.75-1.14]	0.73	[0.55-0.96]	1.06	[0.96-1.15]
Cardiac Arrhythmia	1.04	[0.96-1.13]	1.11	[1.00-1.24]	1.15	[1.00-1.31]	1.09	[1.04-1.15]
Deep Vein Thrombosis	1.33	[1.12-1.57]	1.04	[0.79-1.34]	1.21	[0.89-1.61]	0.88	[0.78-0.99]
Pneumonia	1.60	[1.43-1.79]	1.21	[1.01-1.44]	1.24	[1.00-1.52]	0.81	[0.74-0.88]
Pulmonary Embolism	1.44	[1.20-1.70]	1.17	[0.89-1.50]	1.01	[0.71-1.39]	0.96	[0.85-1.08]
Renal Failure	1.28	[1.17-1.39]	1.13	[0.99-1.27]	1.12	[0.96-1.30]	0.94	[0.89-1.00]
Respiratory Failure	1.53	[1.40-1.66]	0.90	[0.77-1.04]	1.09	[0.92-1.28]	0.80	[0.74-0.85]
Sepsis	1.52	[1.36-1.69]	1.14	[0.95-1.36]	1.15	[0.92-1.40]	0.87	[0.80-0.94]
Urinary Tract Infection	1.01	[0.87-1.15]	1.02	[0.84-1.23]	1.17	[0.94-1.44]	0.97	[0.90-1.05]
437	·				·		·	

# Supplemental Table 6. Comparison of specific 30-day postoperative adverse events based on COVID-19 Severity.

Postoperative Complications	No History of COVID-19 (N = 351,857)	Mild Outpatient WHO Severity 1–3 (N = 31,677)	Moderate Hospitalized without invasive ventilation WHO Severity 4–6 (N= 5,009)	Severe Hospitalized with invasive ventilation or ECMO WHO Severity 7-9 (N= 655)	P value
Mortality	4791 (1.4%)	403 (1.3%)	169 (3.4%)	94 (14%)	<0.001
LOS	2 (0, 6)	2 (0, 5)	4 (1, 9)	12 (4, 29)	<0.001
Hospital Readmission	38175 (11%)	3293 (10%)	832 (17%)	121 (18%)	<0.001
Any Non-Fatal Complication	73555 (21%)	6110 (19%)	1746 (35%)	396 (60%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	723 (2.3%)	243 (4.9%)	53 (8.1%)	<0.001
Cardiac Arrhythmia	34326 (9.8%)	2856 (9.0%)	751 (15%)	142 (22%)	<0.001
Deep Vein Thrombosis	4648 (1.3%)	364 (1.1%)	126 (2.5%)	42 (6.4%)	<0.001
Pneumonia	9623 (2.8%)	704 (2.2%)	249 (5.0%)	138 (21%)	<0.001
Pulmonary Embolism	4296 (1.2%)	388 (1.2%)	99 (2.0%)	32 (4.9%)	<0.001
Renal Failure	22488 (6.4%)	1822 (5.8%)	588 (12%)	180 (27%)	<0.001
Respiratory Failure	18862 (5.4%)	1338 (4.2%)	448 (8.9%)	228 (35%)	<0.001
Sepsis	10244 (2.9%)	764 (2.4%)	271 (5.4%)	151 (23%)	<0.001
Urinary Tract Infection	9662 (2.8%)	791 (2.5%)	214 (4.3%)	39 (6.0%)	<0.001

**Supplemental Table 7.** Multivariable regression assessing the impact of COVID-19 disease severity on composite and specific 30-day postoperative adverse outcomes. All models adjusted for age, sex, race and ethnicity, smoking status, and relative risk of surgery.

	Mild (N = 31,677)	Moderate (N = 5,009)	Severe (N = 655)	
Composite 30-day postoperative outcome	0.96 [0.93-1.00]	1.52 [1.43-1.62]	4.76 [4.01-5.68]	
Mortality	1.00 [0.90-1.11]	1.77 [1.51-2.07]	7.49 [5.93-9.35]	
Composite Non- fatal Complications	0.96 [0.93-0.99]	1.47 [1.38-1.57]	4.08 [3.44-4.84]	
Hospital Readmission	0.96 [0.92-1.00]	1.26 [1.17-1.36]	1.20 [0.98-1.46]	
Myocardial Infarction	0.94 [0.86-1.02]	1.31 [1.13-1.50]	2.02 [1.46-2.73]	
Cardiac Arrhythmia	1.03 [0.98-1.07]	1.27 [1.17-1.38]	2.02 [1.64-2.47]	
Deep Vein Thrombosis	0.87 [0.78-0.97]	1.37 [1.13-1.63]	3.01 [2.16-4.08]	
Pneumonia	0.85 [0.79-0.92]	1.30 [1.14-1.48]	5.53 [4.53-6.70]	
Pulmonary Embolism	1.01 [0.91-1.12]	1.19 [0.96-1.45]	2.56 [1.75-3.60]	
Renal Failure	0.93 [0.88-0.98]	1.28 [1.17-1.40]	3.24 [2.69-3.89]	
Respiratory Failure	0.82 [0.77-0.87]	1.20 [1.08-1.32]	5.71 [4.81-6.76]	
Sepsis	0.85 [0.78-0.91]	1.33 [1.17-1.51]	5.91 [4.88-7.12]	
Urinary Tract Infection	0.93 [0.86-1.00]	1.25 [1.08-1.43]	1.72 [1.22-2.36]	

# **Supplemental Table 8.** Comparison of specific 30-day postoperative adverse events based on vaccination in patients with COVID-19.

Postoperative Complications	Non-Fully Vaccinated (N = 31,973), No. (%)	Fully Vaccinated (N = 5,381), No. (%)	P value
Mortality	585 (1.8%)	81 (1.5%)	0.11
LOS	2 (0, 6)	3 (0, 6)	0.014
Hospital Readmission	3644 (11%)	604 (11%)	0.73
Any Non-Fatal Complication	7072 (22%)	1185 (22%)	0.89
Acute Myocardial Infarction	892 (2.8%)	128 (2.4%)	0.10
Cardiac Arrhythmia	3172 (9.9%)	580 (11%)	0.056
Deep Vein Thrombosis	465 (1.5%)	67 (1.2%)	0.26
Pneumonia	970 (3.0%)	123 (2.3%)	0.003
Pulmonary Embolism	434 (1.4%)	85 (1.6%)	0.22
Renal Failure	2245 (7.0%)	347 (6.4%)	0.13
Respiratory Failure	1792 (5.6%)	225 (4.2%)	<0.001
Sepsis	1042 (3.3%)	146 (2.7%)	0.039
Urinary Tract Infection	873 (2.7%)	172 (3.2%)	0.061

#### DISCLAIMER

457

458

459

460

461

462 463

464

465

466

467

468

469

470

471

472

473

474

475 476

502503

504

The N3C Publication committee confirmed that this manuscript (MSID: 1004.67) is in accordance with N3C data use and attribution policies; however, the content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Authorship was determined using ICMJE recommendations.

### **ACKNOWLEDGEMENT**

The analyses described in this publication were conducted under the DUR RP-A39709 and IRB #PRO00042159 with data or tools accessed through the NCATS N3C Data Enclave covid.cd2h.org/enclave and supported by CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1 TR001436 and 3UL1TR001436-08S3. Additional funding support provided by Advancing a Healthier Wisconsin Endowment. This research was possible because of the patients whose information is included within the data from participating organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas) who have contributed to the on-going development of this community resource (https://doi.org/10.1093/jamia/ocaa196).

We gratefully acknowledge the following core contributors to N3C:

477 Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit 478 Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin, 479 Anita Walden, Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, 480 Brijesh Patel, Caleb Alexander, Carolyn Bramante, Cavin Ward-Caviness, Charisse Madlock-481 Brown, Christine Suver, Christopher Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff 482 Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Don Brown, 483 Eilis Boudreau, Elaine Hill, Elizabeth Zampino, Emily Carlson Marti, Emily R. Pfaff, Evan 484 French, Farrukh M Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold 485 Lehmann, Heidi Spratt, Hemalkumar Mehta, Hongfang Liu, Hythem Sidky, J.W. Awori Hayanga, 486 Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Islam, Jin Ge, Joel Gagnier, Joel 487 H. Saltz, Joel Saltz, Johanna Loomba, John Buse, Jomol Mathew, Joni L. Rutter, Julie A. 488 McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M. 489 Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Dwain Cato, Kimberly Murray, Kristin 490 Kostka, Lavance Northington, Lee Allan Pyles, Leonie Misquitta, Lesley Cottrell, Lili Portilla, 491 Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Mary Morrison Saltz, Matvey B. 492 Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple-O'Connor, Michael G. Kurilla, 493 Michele Morris, Nabeel Qureshi, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, 494 Patricia A. Francis, Penny Wung Burgoon, Peter Robinson, Philip R.O. Payne, Rafael Fuentes, 495 Randeep Jawa, Rebecca Erwin-Cohen, Rena Patel, Richard A. Moffitt, Richard L. Zhu, Rishi 496 Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel 497 Bozzette, Sandeep Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko 498 Setoquchi, Stephanie S. Hong, Steve Johnson, Tellen D. Bennett, Tiffany Callahan, Umit 499 Topaloglu, Usman Sheikh, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy 500 Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang. Details of 501 contributions available at covid.cd2h.org/core-contributors

The following institutions whose data is released or pending:

- Available: Advocate Health Care Network UL1TR002389: The Institute for Translational
- 505 Medicine (ITM) Boston University Medical Campus UL1TR001430: Boston University
- 506 Clinical and Translational Science Institute Brown University U54GM115677: Advance
- 507 Clinical Translational Research (Advance-CTR) Carilion Clinic UL1TR003015: iTHRIV

```
508
       Integrated Translational health Research Institute of Virginia • Charleston Area Medical Center
509

    U54GM104942: West Virginia Clinical and Translational Science Institute (WVCTSI)

510
       Children's Hospital Colorado — UL1TR002535: Colorado Clinical and Translational Sciences
511
       Institute • Columbia University Irving Medical Center — UL1TR001873: Irving Institute for
512
       Clinical and Translational Research • Duke University — UL1TR002553: Duke Clinical and
513
       Translational Science Institute • George Washington Children's Research Institute —
514
       UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN) •
515
       George Washington University — UL1TR001876: Clinical and Translational Science Institute at
516
       Children's National (CTSA-CN) • Indiana University School of Medicine — UL1TR002529:
       Indiana Clinical and Translational Science Institute • Johns Hopkins University —
517
518
       UL1TR003098: Johns Hopkins Institute for Clinical and Translational Research • Loyola
519
       Medicine — Loyola University Medical Center • Loyola University Medical Center —
520
       UL1TR002389: The Institute for Translational Medicine (ITM) • Maine Medical Center —
521
       U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network •
522
       Massachusetts General Brigham — UL1TR002541: Harvard Catalyst • Mayo Clinic Rochester
523
       — UL1TR002377: Mayo Clinic Center for Clinical and Translational Science (CCaTS) • Medical
524
       University of South Carolina — UL1TR001450: South Carolina Clinical & Translational
525
       Research Institute (SCTR) • Montefiore Medical Center — UL1TR002556: Institute for Clinical
526
       and Translational Research at Einstein and Montefiore • Nemours — U54GM104941: Delaware
527
       CTR ACCEL Program • NorthShore University HealthSystem — UL1TR002389: The Institute for
528
       Translational Medicine (ITM) • Northwestern University at Chicago — UL1TR001422:
529
       Northwestern University Clinical and Translational Science Institute (NUCATS) • OCHIN — INV-
530
       018455: Bill and Melinda Gates Foundation grant to Sage Bionetworks • Oregon Health &
531
       Science University — UL1TR002369: Oregon Clinical and Translational Research Institute •
532
       Penn State Health Milton S. Hershey Medical Center — UL1TR002014: Penn State Clinical and
533
       Translational Science Institute • Rush University Medical Center — UL1TR002389: The Institute
534
       for Translational Medicine (ITM) • Rutgers, The State University of New Jersey —
535
       UL1TR003017: New Jersey Alliance for Clinical and Translational Science • Stony Brook
536
       University — U24TR002306 • The Ohio State University — UL1TR002733: Center for Clinical
537
       and Translational Science • The State University of New York at Buffalo — UL1TR001412:
538
       Clinical and Translational Science Institute • The University of Chicago — UL1TR002389: The
539
       Institute for Translational Medicine (ITM) • The University of Iowa — UL1TR002537: Institute for
540
       Clinical and Translational Science • The University of Miami Leonard M. Miller School of
541
       Medicine — UL1TR002736: University of Miami Clinical and Translational Science Institute •
542
       The University of Michigan at Ann Arbor — UL1TR002240: Michigan Institute for Clinical and
543
       Health Research • The University of Texas Health Science Center at Houston —
544
       UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • The University of Texas
545
       Medical Branch at Galveston — UL1TR001439: The Institute for Translational Sciences • The
546
       University of Utah — UL1TR002538: Uhealth Center for Clinical and Translational Science •
547
       Tufts Medical Center — UL1TR002544: Tufts Clinical and Translational Science Institute •
548
       Tulane University — UL1TR003096: Center for Clinical and Translational Science • University
549
       Medical Center New Orleans — U54GM104940: Louisiana Clinical and Translational Science
550
       (LA CaTS) Center • University of Alabama at Birmingham — UL1TR003096: Center for Clinical
551
       and Translational Science • University of Arkansas for Medical Sciences — UL1TR003107:
552
       UAMS Translational Research Institute • University of Cincinnati — UL1TR001425: Center for
553
       Clinical and Translational Science and Training • University of Colorado Denver, Anschutz
554
       Medical Campus — UL1TR002535: Colorado Clinical and Translational Sciences Institute •
555
       University of Illinois at Chicago — UL1TR002003: UIC Center for Clinical and Translational
       Science • University of Kansas Medical Center — UL1TR002366: Frontiers: University of
556
557
       Kansas Clinical and Translational Science Institute • University of Kentucky — UL1TR001998:
```

UK Center for Clinical and Translational Science • University of Massachusetts Medical School

```
559
       Worcester — UL1TR001453: The UMass Center for Clinical and Translational Science
560
       (UMCCTS) • University of Minnesota — UL1TR002494: Clinical and Translational Science
       Institute • University of Mississippi Medical Center — U54GM115428: Mississippi Center for
561
562
       Clinical and Translational Research (CCTR) • University of Nebraska Medical Center –
563
       U54GM115458: Great Plains IDeA-Clinical & Translational Research • University of North
564
       Carolina at Chapel Hill — UL1TR002489: North Carolina Translational and Clinical Science
565
       Institute • University of Oklahoma Health Sciences Center — U54GM104938: Oklahoma Clinical
566
       and Translational Science Institute (OCTSI) • University of Rochester — UL1TR002001: UR
567
       Clinical & Translational Science Institute • University of Southern California — UL1TR001855:
568
       The Southern California Clinical and Translational Science Institute (SC CTSI) • University of
569
       Vermont — U54GM115516: Northern New England Clinical & Translational Research (NNE-
570
       CTR) Network • University of Virginia — UL1TR003015: iTHRIV Integrated Translational health
571
       Research Institute of Virginia • University of Washington — UL1TR002319: Institute of
572
       Translational Health Sciences • University of Wisconsin-Madison — UL1TR002373: UW
573
       Institute for Clinical and Translational Research • Vanderbilt University Medical Center —
574
       UL1TR002243: Vanderbilt Institute for Clinical and Translational Research • Virginia
575
       Commonwealth University — UL1TR002649: C. Kenneth and Dianne Wright Center for Clinical
576
       and Translational Research • Wake Forest University Health Sciences — UL1TR001420: Wake
577
       Forest Clinical and Translational Science Institute • Washington University in St. Louis —
578
       UL1TR002345: Institute of Clinical and Translational Sciences • Weill Medical College of Cornell
579
       University — UL1TR002384: Weill Cornell Medicine Clinical and Translational Science Center •
580
       West Virginia University — U54GM104942: West Virginia Clinical and Translational Science
581
       Institute (WVCTSI)
582
       Submitted: Icahn School of Medicine at Mount Sinai — UL1TR001433: ConduITS Institute for
583
       Translational Sciences • The University of Texas Health Science Center at Tyler —
584
       UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • University of California,
585
       Davis — UL1TR001860: UCDavis Health Clinical and Translational Science Center • University
586
       of California, Irvine — UL1TR001414: The UC Irvine Institute for Clinical and Translational
587
       Science (ICTS) • University of California, Los Angeles — UL1TR001881: UCLA Clinical
588
       Translational Science Institute • University of California, San Diego — UL1TR001442: Altman
589
       Clinical and Translational Research Institute • University of California, San Francisco —
590
       UL1TR001872: UCSF Clinical and Translational Science Institute
591
       Pending: Arkansas Children's Hospital — UL1TR003107: UAMS Translational Research
592
       Institute • Baylor College of Medicine — None (Voluntary) • Children's Hospital of Philadelphia
593
       — UL1TR001878: Institute for Translational Medicine and Therapeutics • Cincinnati Children's
594
       Hospital Medical Center — UL1TR001425: Center for Clinical and Translational Science and
595
       Training • Emory University — UL1TR002378: Georgia Clinical and Translational Science
596
       Alliance • HonorHealth — None (Voluntary) • Loyola University Chicago — UL1TR002389: The
       Institute for Translational Medicine (ITM) • Medical College of Wisconsin — UL1TR001436:
597
598
       Clinical and Translational Science Institute of Southeast Wisconsin • MedStar Health Research
599
       Institute — UL1TR001409: The Georgetown-Howard Universities Center for Clinical and
600
       Translational Science (GHUCCTS) • MetroHealth — None (Voluntary) • Montana State
601
       University — U54GM115371: American Indian/Alaska Native CTR • NYU Langone Medical
602
       Center — UL1TR001445: Langone Health's Clinical and Translational Science Institute •
603
       Ochsner Medical Center — U54GM104940: Louisiana Clinical and Translational Science (LA
604
       CaTS) Center • Regenstrief Institute — UL1TR002529: Indiana Clinical and Translational
       Science Institute • Sanford Research — None (Voluntary) • Stanford University —
605
606
       UL1TR003142: Spectrum: The Stanford Center for Clinical and Translational Research and
607
       Education • The Rockefeller University — UL1TR001866: Center for Clinical and Translational
608
       Science • The Scripps Research Institute — UL1TR002550: Scripps Research Translational
```

Institute • University of Florida — UL1TR001427: UF Clinical and Translational Science Institute

University of New Mexico Health Sciences Center — UL1TR001449: University of New Mexico Clinical and Translational Science Center • University of Texas Health Science Center at San Antonio — UL1TR002645: Institute for Integration of Medicine and Science • Yale New Haven Hospital — UL1TR001863: Yale Center for Clinical Investigation